Despite its initial promise as a CD36 inhibitor to treat ovarian cancer, it was thereafter abandoned, as phase II clinical trials of ABT510 treatment in advanced renal cell carcinoma [185], soft tissue sarcoma [186] and metastatic melanoma [187] showed it lacked sufficient clinical efficiency. This evidence concerns the gene CD36 and ovarian cancer.